만성 C형 간염 치료의 최근 발전
Recent Advancement in the Treatment of Chronic Hepatitis C
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Currently, the most widely prescribed standard therapy for chronic hepatitis C consists of pegylated-interferon combined withribavirin. Although the response rate to interferon-based treatments has improved since interferon monotherapy was first combinedwith ribavirin, and then pegylated-interferon was adopted, patients eligible for this treatment are limited; the side effects are unbearablein some patients, and the response rates are still unsatisfactory for those who have unfavorable clinical features. Achievements in molecular research have led to the discovery of enormous molecules with anti-hepatitis C virus (HCV) activity. Telaprevir, boceprevir, simeprevir, and sofosbuvir have already been approved by the U.S. Food and Drug Administration andmany new drugs are being evaluated in ongoing clinical trials. We review the clinical efficacy of approved new anti-HCV drugs,along with many promising treatment options under development.
Abstract
Currently, the most widely prescribed standard therapy for chronic hepatitis C consists of pegylated-interferon combined withribavirin. Although the response rate to interferon-based treatments has improved since interferon monotherapy was first combinedwith ribavirin, and then pegylated-interferon was adopted, patients eligible for this treatment are limited; the side effects are unbearablein some patients, and the response rates are still unsatisfactory for those who have unfavorable clinical features. Achievements in molecular research have led to the discovery of enormous molecules with anti-hepatitis C virus (HCV) activity. Telaprevir, boceprevir, simeprevir, and sofosbuvir have already been approved by the U.S. Food and Drug Administration andmany new drugs are being evaluated in ongoing clinical trials. We review the clinical efficacy of approved new anti-HCV drugs,along with many promising treatment options under development.
참고문헌 (27)
- Choo QL, "Isolation of a cDNA clone derived from a blood-borne nonA, nonB viral hepatitis genome", Science, 244, pp.359~362 (1989)
- Kim TH, "Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy", Intervirology, 48, pp.230~238 (2005)
- Conteduca V, "Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents", J Infect, 68, pp.1~20 (2014)
- Scheel TK, "Understanding the hepatitis C virus life cycle paves the way for highly effective therapies", Nat Med, 19, pp.837~849 (2013)
- Bartenschlager R, "The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection", Nat Rev Microbiol, 11, pp.482~496 (2013)
- Au JS, "Novel therapeutic approaches for hepatitis C", Clin Pharmacol Ther, 95, pp.78~88 (2014)
- Janssen HL, "Treatment of HCV infection by targeting microRNA", N Engl J Med, 368, pp.1685~1694 (2013)
- Chen J, "Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies", Gastroenterology, 144, pp.1450~1455 (2013)
- Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
- Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
- Ali A, "Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3", 4A protease inhibitors to drug resistance, 2013, pp.8, 1469~1478
- Suzuki F, "Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b", J Clin Virol, 54, pp.352~354 (2012)
- Jacobson I, "Simeprevir (TMC435) with peginterferon", ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial, 2013, pp.58, S574~
- Manns M, "Simeprevir (TMC435) with peginterferon", ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial, 2013, pp.58, S568~
- Forns X, "Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial", Gastroenterology (2014)
- Kowdley KV, "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial", Lancet, 381, pp.2100~2107 (2013)
- Lawitz E, "Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial", Lancet Infect Dis, 13, pp.401~408 (2013)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- Koff RS, "Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection", Aliment Pharmacol Ther, 39, pp.478~487 (2014)
- Zeuzem S, "Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial", Hepatology, 58, pp.733A~ (2013)
- Jacobson IM, "SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: The COSMOS study", Hepatology, 58, pp.1379A~ (2013)
- Sulkowski MS, "Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial", Hepatology, 57, pp.2143~2154 (2013)
- Sulkowski MS, "Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial", Hepatology, 57, pp.2155~2163 (2013)
- Zeuzem S, "Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results", Antivir Ther, 18, pp.1015~1019 (2013)
- Zeuzem S, "Faldaprevir and deleobuvir for HCV genotype 1 infection", N Engl J Med, 369, pp.630~639 (2013)
- Knowdley KV, "Safety and efficacy of interferon-free regimens of ABT-450", r, ABT-267, ABT-333 +, J Hepatol, pp.2013, 58[DOI]
- "Recommendations for Testing, Managing, and Treating Hepatitis C" (2014)[URL]